Trials / Unknown
UnknownNCT01417858
Intraocular Pressure Control After Anterior Segment Laser - Comparison Between 2 Drugs
Short-term Intraocular Pressure Control After YAG Iridotomy - Comparison Between Brimonidine 0.1% vs. 0.2%
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Universidade Federal do Paraná · Academic / Other
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the intra-ocular (IOP) control efficacy between brimonidine 0.1% vs. 0.2% after laser peripheral iridotomy (LPI).
Detailed description
Postoperative IOP elevation is one of the most common complications after LPI.Previous studies showed that brimonidine 0.2% is effective in blunting IOP spikes after LPI.This prospective randomized double-masked interventional study will include patients with bilateral narrow angles, defined by irido-trabecular contact in \>180o on gonioscopy.Pilocarpine 1% will be used in both eyes, and 30 minutes later, brimonidine 0.1% randomly used in one eye and brimonidine 0.2% in the contra-lateral eye. LPI with Nd:YAG laser is performed 30 minutes later in both eyes by a single glaucoma specialist. IOP measurements are assessed before the use of any eyedrop (basal IOP), 30 minutes after pilocarpine (pre-brimonidine), and 30, 60, 120, 180 minutes after LPI. Pachymetry, ultrasonic biometry, gonioscopy, and total YAG laser energy are recorded. Non-parametric test will be used for analysis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | YAG laser peripheral iridotomy | 1 drop 30 minutes before yag laser iridotomy |
| PROCEDURE | YAG laser peripheral iridotomy | 1 drop 30 minutes before yag laser iridotomy |
Timeline
- Start date
- 2010-11-01
- Primary completion
- 2011-12-01
- Completion
- 2012-07-01
- First posted
- 2011-08-16
- Last updated
- 2011-08-16
Locations
1 site across 1 country: Brazil
Source: ClinicalTrials.gov record NCT01417858. Inclusion in this directory is not an endorsement.